Ambrx Biopharma (AMAM) announced that the Company will be added to the NASDAQ Biotechnology Index (NBI), effective prior to the market open on Monday, December 18, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMAM:
- Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
- Ambrx Biopharma provides update on APEX-01
- Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- Ambrx Biopharma price target lowered to $22 from $26 at Baird